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Abstract
We previously discovered that a fat-metabolizing
enzyme, 15-lipoxygenase-1 (15-LO-1), is high in human
prostate cancer (PCa) and correlates with disease
progression. The biologic link between the aberrant
15-LO-1/linoleic acid (LA) metabolism and fat (which is
a rich source of growth factors) in PCa is unknown.
Therefore, we tested the hypothesis that the metabolic
product of the polyunsaturated fatty acid LA (i.e., 13-S-
hydroxyoctadecadienoic acid or 13-(S)-HODE) affects
the proliferation status of PCa cells through one or
more growth factors. We used parental prostate cancer
cell line-3 (PC-3) and engineered PC-3 cell lines [PC3-
Zeo (mock-transfected), PC3-15LOS (15-LO-1–overex-
pressing), and PC3-15LOAS (15-LO-1–blocked)] to test
our hypothesis. Of the growth factors examined, only
insulin-like growth factor-1 (IGF-1) exhibited a two-fold
to three-fold increase in growth response on PC3-
15LOS cells compared to PC3-Zeo (control) cell line
(P < .01). Insulin-like growth factor-1 receptor (IGF-1R)
immunohistochemical analyses of human normal and
adenocarcinoma prostate tissues, as well as levels in
tumors derived from nude mice injected with PC-3
cells, demonstrated that elevated IGF-1R expression
correlated with 15-LO-1 levels. Radioligand binding
assays demonstrated two-fold higher IGF-1 binding
sites in PC3-15LOS cells (P < .05 vs PC3-Zeo cells).
IGF-1R promoter reporter assay and affinity-purified
IGF-1R receptor levels demonstrated a four-fold higher
activity in PC3-15LOS cells (P < .01 vs PC3-Zeo cells).
IGF-1R promoter activation is 13-(S)-HODE–dependent.
IGF-1R blockade with a dominant-negative adenovirus
caused significant growth inhibition in PC-3 cells
(P < .0001; PC3-15LOAS versus PC3-15LOS cells), as
well as affected the IGF-1–stimulated mitogen-acti-
vated protein (MAP) kinase (Erk1/2) and Akt activation
levels. Our study suggests that overexpression of 15-
LO-1 in PCa contributes to the cancer progression by
regulating IGF-1R expression and activation.
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Introduction
In 2003, 220,900 men were diagnosed with prostate cancer
(PCa) in the United States. Approximately 28,900 died of the
disease in 2003 (American Cancer Society—Facts and
Figures, 2003). Current therapies [1] for PCa are limited,
and there is no cure for metastatic disease. Oncogenic signals
involve activation of membrane receptors, kinases, and tran-
scription factors. These can be either a primary event, when
they are directly mutated in a tumor cell, or a secondary event,
as recipients and mediators of oncogenic signals. Of note is
that epigenetic factors such as diets high in fat seem to be
associated with an increased risk of PCa, although the mo-
lecular mechanism is still unknown.
Dietary lipids are metabolized by cyclooxygenases (COX-1
and/or COX-2 [2]) or lipoxygenases (5-LO [3], 12-LO [4], 15-
LO-1 [5,6], and 15-LO-2 [7]), but the precise role of these
enzymes (or enzymatic products) in PCa is an area of active
investigation. As principal macronutrients in today’s diet, the
n6 series of dietary fatty acids is known to play a prominent
role in cancers. An important member of this group is linoleic
acid [LA; n6 polyunsaturated fatty acid (PUFA), C18:2n6],
which is an essential PUFA found in sunflower and peanut oils.
15-Lipoxygenase-1 (15-LO-1) metabolizes LA to 13-S-hydroxy-
octadecadienoic acid [13-(S)-HODE], which can regulate cell
growth and differentiation and vascular homeostasis [8–24].
Our previously published findings [6,17] and other reports
strongly suggest that 13-(S)-HODE enhances cellular prolifer-
ation [8–18,21–24]. While investigating the cellular and molec-
ular biology of the ‘‘anti-inflammatory’’ properties of 15-LO-1, we
discovered that 15-LO-1 gene expression is upregulated by a
mutant form of p53, although no effect was seen with wild-type
p53 [18]. The p53 protein is a tumor suppressor and mutations
in it are often associated with the development of cancer.
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Furthermore, we observed higher 15-LO-1 expression
and enzyme activity in the epithelium of human PCa com-
pared to the normal surrounding tissues; the higher level of
15-LO-1 also correlated with the degree of malignancy, as
assessed by Gleason grades. Interestingly, the level of
mutant p53 is also correlated with the level of 15-LO-1 [6].
Recently, we developed a human PCa cell line, prostate
cancer cell line-3 (PC-3), that either overexpresses 15-LO-1
(PC3-15LOS cells) or expresses 15LOAS (antisense) mRNA
to block endogenous 15-LO-1 (PC3-15LOAS cells), and
shows that only PC3-15LOS cells, when injected subcuta-
neously in athymic mice, produce aggressive tumors ex-
hibiting augmented angiogenesis [17]. Although our
experimental observations suggest a correlation between
15-LO-1 activity and tumorigenesis [6,17], the mechanism
of 15-LO-1 overexpression linking tumorigenesis is un-
known. Based on our previous observations, we hypothesize
that ‘‘mitogenic’’ 13-(S)-HODE may be acting as a signaling
molecule to support both prolonged survival and increased
proliferation of prostate epithelial cells. The overexpression
of 15-LO-1 specifically in the normal prostate epithelium
could be one of the contributory factors facilitating the
progression to high-grade intraepithelial neoplasia (HGPIN;
Kelavkar et al., unpublished results) and eventually to pros-
tate adenocarcinoma. It has been recently shown that the
insulin-like growth factor (IGF) signaling pathway is linked to
PCa and that 13-(S)-HODE (the LA metabolite) upregu-
lated—and 15-(S)-hydroxyeicosatetraenoic acid (15-(S)-
HETE; the arachidonic acid metabolite) downregulated—
both the mitogen-activated protein kinase (MAPK) and Akt
pathways after activation with insulin-like growth factor-1
(IGF-1) [24]. Therefore, in a likely scenario, the epithelial
cells of primary prostate tumor overexpressing 15-LO-1 may
support interactions with stromal elements (e.g., growth
factors) and facilitate invasion.
This manuscript describes experiments designed to
show that the overexpression of a lipid-metabolizing en-
zyme, 15-LO-1, regulates Insulin-like growth factor-1 recep-
tor (IGF-1R) expression and activation and thereby affects
the proliferation status of PCa cells (PC-3 cell line) in vitro
and in vivo. Our goal is to provide a mechanism that explains
the observation that diets high in fat appear to be associated
with an increased risk of PCa. The series of experiments
utilizes our previously developed PC-3 cell line that either
overexpresses 15LOS (sense) or expresses 15LOAS (anti-
sense) mRNA, and our objectives were as follows: 1) to test
whether 13-(S)-HODE, which is a metabolic product of the
fatty acid LA (metabolized by 15-LO-1), reverses the growth
inhibition of PC cells by PD146176; 2) compare the expres-
sion of IGF-1R in 10 normal and 16 PCa tissues by image
cytometry; 3) measure differences in IGF-1R levels in tumors
from four nude mice, injected with different types of PC-3
cells, by immunohistochemistry; 4) evaluate whether 15-
LO-1 expression causes IGF-l R activation (phosphorylation)
by performing Western blot analyses; 5) evaluate whether
15-LO-1 affects IGF-1R promoter activity by measuring the
relative luciferase activity in the different PC-3 cell lines; 6)
explore the impact of 13-(S)-HODE on IGF-1R promoter
(reporter activity) by treating PC3-Zeo (control) cells with
increasing doses of 13-(S)-HODE; 7) determine whether
targeting IGF-1R can block PC-3 proliferation and whether
growth inhibition differs for PC-3 cells overexpressing 15-
LO-1; and 8) evaluate whether 15-LO-1–mediated IGF-1R
expression affects MAPK activation.
Materials and Methods
Cell Culture
PC-3 parental PCa epithelial cells (CRL-1435) were
obtained from the American Type Culture Collection (ATCC;
Manassas, VA) and cultured in RPMI medium (Gibco-BRL,
Carlsbad, CA) without phenol red, containing 10% fetal
bovine serum (FBS) (complete medium) per milliliter in 5%
CO2 at 37jC. The cells were split after every 3 days. The
stable PC-3 transfectants used in this study are as described
previously [17]. PC3-15LOS (15-LO-1–overexpressing) and
PC3-Zeo (mock-transfected) were grown in a medium con-
taining 50 mg/ml Zeocin (Invitrogen, Carlsbad, CA).
Antibodies
The isotypes and specificities of monoclonal and poly-
clonal antibodies are as follows: polyclonal CheY antibody
IgG1 is specific for 15-LO-1 (obtained from Dr. Elliott
Sigal), monoclonal antibody IgG1 is specific for human
IGF-1Ra (N-20) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), and a general anti–phosphotyrosine antibody
PY-7E1 (Zymed Laboratories, Inc., San Francisco, CA) is
used. For Akt, an antibody specific for phospho-Akt (Ser
473) is used, and for Erk1/2, phospho-p44/42 MAP kinase
(Thr 202/Tyr 204) is used (New England Biolaboratories,
Beverly, MA). Similarly, antibodies recognizing total
IGF-1R, ERK, and Akt proteins are also used individually
(New England Biolaboratories).
Cell Growth Assays
PC-3 cells and their genetically engineered 15-LO-1
derivatives were tested for proliferation using the Boehringer
Mannheim Cell Proliferation Kit (MTT) (Boehringer Mann-
heim, Ridgefield, CT). PC-3 cells were plated on 24-well
plates (50,000–80,000 cells/well) and maintained overnight
in complete medium. Cells were then changed to serum-free
medium in the absence or presence of IGF-1 (10 ng/ml
medium) and treated with different adenoviruses as de-
scribed in the text. At the indicated time periods, the medium
was aspirated from the wells, and 200 ml of MTT reagent
(1 mg/ml) was added to each well. The cells were then
incubated for 1 hour at 37jC and lysed by addition of 200 ml
of isoamyl alcohol and shaking for 20 minutes. A 200-ml
aliquot of each sample was then translated to 96-well plates
and read in an enzyme-linked immunosorbent assay reader
at 570 to 690 nm. The percentage increase (corrected
absorbance) in cell proliferation was measured. Cells grown
in parallel were also harvested and survival was estimated
from those that excluded 0.2% trypan blue [17].
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Immunohistochemical and Image Cytometric Quantitation
Analyses of Human Prostate Tissues and Tumor Samples
from Athymic Mice
Experiments performed with tumor tissues from mouse
and human prostate tissues were carried out according to the
guidelines of the Committees on Experimental Animals and
Human Tissue Use of the University of Pittsburgh.
Sections of formalin-fixed, paraffin-embedded tissues
(5 mm) were tested for the presence of IGF-1R (1:200), using
an avidin biotin complex technique, steam heat– induced
antigen retrieval, anddiaminobenzidine (DAB) staining brown,
quantitated by image cytometry as described previously [6].
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and Western Blot Analysis
Western blot analysis of IGF-1R,MAP kinase (Erk1/2), and
Akt was performed similarly as previously described [6].
Protein was measured by the method of Bradford [25]. Briefly,
25 mg of protein whole cell extracts or immunoprecipitated
samples was separated on SDS gels and transferred onto
individual PVDF membranes by electroblotting. Ponceau S
staining of the blots was conducted to ensure equivalent
protein loading. The nitrocellulosemembraneswere incubated
with their respective antibodies (1:10,000 dilution) for 1 hour
at room temperature. Following incubation with appropriate
IgG peroxidase second antibody (1:8000), proteins were
visualized by using the Luminol/Enhancer (ECL) solutions as
described by the manufacturer. The intensity of phosphoryla-
tion value is quantified by densitometric intensity values, nor-
malized by dividing the intensity value of the total protein band.
Transient Transfection and Dual-Luciferase Assay
Transient transfections were carried out using luciferase
reporter construct (a plasmid containing the luciferase gene
driven by base pairs 2350 to +640 of the rat IGF-1R
promoter region) [26], along with a Renilla expression vector
as a control for transfection efficiency. The luciferase activity,
as ameasure of IGF-1R activation, was normalized to Renilla
in each case. Cells were plated at 40% confluence in 12-well
plates. After 24 hours, the plasmid DNA (1 mg) was individ-
ually cotransfected with the Renilla coreporter, Rluc (Prom-
ega,Madison,WI), into PC-3 cells by FuGENE6Transfection
reagent (Boehringer Mannheim). The cells were grown for
24 hours before being harvested for assays. For assays, the
cells were trypsinized and washed thrice with phosphate-
buffered saline (PBS). The cell extracts were prepared
with 400 ml of reporter lysis buffer (Promega) and clarified
by centrifugation at 20,000g at 4jC for 2 minutes, and
the supernatant was transferred to a new tube. The clarified
supernatants were individually analyzed for dual-luciferase
reporter assays (100 ml) using a luminometer with auto-
injector (Turner design), as described by the manufacturer
(Promega).
Dominant-Negative IGF-1R Adenoviral Vector
(AdTrackCMV-DNIGF-1R-GFP)
For IGF-1R blocking, recombinant adenovirus (Ad-
TrackCMV-DNIGF-1R-GFP) that contains a dominant
negative a chain of the receptor was used. There is high
homology of IGF-1R among humans and rats (98% at the
protein level) that allows the use of dominant-negative IGF-
1R from rats in studies with human cells [26,27]. It encodes
amino acids 1 to 952 of the rat IGF-1 receptor, has an
influenza hemagglutinin epitope (HA1) tag, and a TGA (stop
codon). The basic pAdTrackCMV-GFP vector (a gift of
Dr. Vogelstein, Baltimore, MD) is used to produce green
fluorescent protein (GFP)– trackable viruses containing
transgenes. Briefly, the dominant-negative IGF-1R was
subcloned into a pAdTrackCMV-GFP vector as described
[28] to produce AdTrackCMV-DNIGF-1R-GFP. The efficien-
cy of both the control pAdTrackCMV-GFP as well as the
dominant-negative AdTrackCMV-DNIGF-1R-GFP adenovi-
rus-infected PC-3 parental cells was found to be 90% by
GFP expression (data not shown). To generate higher titer
viral stocks of both vectors, 293 cells are reinfected until a
total of 5  108 packaging cells and generally a range of 1.16
to 2.2  1011 plaque-forming units (pfu) are obtained, and
we used 1.16  1011 pfu for our experiments. The viruses
are purified by cesium chloride (CsCl) gradient centrifugation
and stored in liquid nitrogen. Just before conducting the
actual experiments, both adenoviruses are individually dia-
lyzed against water and used immediately.
Binding Assays and Scatchard Analysis
Binding assay for IGF-1 was performed with PC-3 cells
using tracer amounts of [125I]IGF-1 (2000 Ci/mmol specific
activity; Amersham Life Science, Inc., Arlington Heights, IL).
Cells were plated in 24-well culture dishes and grown to 80%
confluence. A total of 100,000 cells/well was then washed
four times with Hepes buffer containing 10 mM Hepes, 135
mM NaCl, 4.8 mM KCl, 1.7 mM MgSO4, 2.5 mM CaCl2, and
1.0 mM NaH2PO4, pH 7.4, followed by incubation of the cells
for 30 minutes at 37jC with [125I]IGF-1, in the presence or
absence of different concentrations (5–100 nM) of IGF-1.
After incubation, the cells were washed with ice-cold Hepes
buffer and lysed in 0.1 M NaOH, and radioactivity was
counted by g-counter. The binding was analyzed by Scatch-
ard analysis as described [29].
Statistical Analyses
All experimental data are representative of experiments
performed at least in triplicates. Data are expressed as
mean ± standard error (SE) or SD. The criterion for statistical
significance was taken as P < .05.
Results
Survival of PC-3 Cells Depends on the LA Product of
15-LO-1: 13-(S)-HODE
We previously showed that PD146176, a specific 15-LO-1
enzyme inhibitor [30], inhibited the proliferation of cultured
PC-3 cells (i.e., parental PC-3, mock-transfected PC3-Zeo,
and 15-LO-1–overexpressing PC3-15LOS) in a concentra-
tion-dependent manner (complete inhibition at 1 M concen-
tration) [17]. However, PD146176 did not completely inhibit
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the growth of PC3-15LOAS cells that do not express 15-LO-
1 enzyme [17]. This result suggested that the growth inhibi-
tion of PC-3 cells by PD146176 was dependent on 15-LO-1
expression and enzyme activity. PC3-15LOS cells produced
increased 13-(S)-HODE levels, and grew faster compared to
PC3-Zeo, PC3 parental, and PC3-15LOAS cells, respective-
ly [17]. Although 15-LO-1 preferentially metabolizes LA to
13-(S)-HODE, it also can substantially convert arachidonic
acid to 15-(S)-HETE. Therefore, in order to rule out the
15-(S)-HETE effects attributed by the arachidonic acid me-
tabolism, we initially performed experiments using 10 mM
each of 15-(S)-HETE as well as with an inactive enantiomer
of 13-(S)-HODE, called 13-(R)-HODE, as a control, respec-
tively. We did not observe any significant growth differences
in any of the PC-3 cell lines with 15-(S)-HETE and 13-(R)-
HODE, respectively (data not shown).
Although 15-(S)-HETE and 13-(R)-HODE did not cause
differences in growth of PC-3 cells, we further investigated
the importance and specificity of 15-LO-1 to determine
whether 13-(S)-HODE, 13-(R)-HODE (inactive), and
15-(S)-HETE (arachidonic acid metabolite) could reverse
the growth inhibition caused by PD146176. We added
10-mM concentrations of 13-(S)-HODE, 13-(R)-HODE, and
15-(S)-HETE (replaced by fresh media every 12 hours)
in vitro to the PC-3 cells treated with 1 M PD146176. Our
results illustrate that the growth inhibition of PC-3 cells by
PD146176 is rescued or reversed only by 13-(S)-HODE
(Figure 1A), and not by 13-(R)-HODE or 15-(S)-HETE (data
not shown), respectively. These data suggest that 15-LO-1
[13-(S)-HODE] specifically supports proliferation, as well as
survival, of PC-3 cells. Therefore, the effects of 15-(S)-HETE
and 13-(R)-HODE were not evaluated in further studies.
There Is a Link Between 15-LO-1 Overexpression and
Stromal Element (IGF-1), Which Together Support
Prostate Epithelial Cell Proliferation
While further characterizing the phenotypes of PC-3 cell
lines, we observed that the growth factors such as platelet-
derived growth factor (PDGF), IGF-1, and basic fibroblast
growth factor (bFGF), when added exogenously in serum-
starved growth medium, also participated in cell growth.
However, there is a potential limitation when comparing the
growth induction in these cells because of the differences in
growth and phenotypes. Therefore, it seems that the prolif-
eration (by MTT assay) is similar (i.e., three-fold to four-fold)
comparing PC3-Zeo and PC3-Zeo treated with IGF-1, and
then comparing PC3-15LOS and PC3-15LOS treated with
IGF-1) and that there is no clear margin to show that IGF-1 is
significantly more growth-promoting than FGF and PDGF
(Figure 1B).
Interestingly, only the PC3-15LOS (15-LO-1–overex-
pressing) cells exhibited a two-fold to three-fold greater
response (n = 6, P < 0.01, if compared with PC3-Zeo cells)
to IGF-1 in 72 hours (Figure 1B). These results suggested
that the proliferation of 15-LO-1–overexpressing PC3-
15LOS cells may be modulated by IGF-1 consequently via
the IGF-1 receptor (IGF-1R). Thus, we hypothesized that the
differences observed in the IGF-1 effects on growth capabil-
ity of PC-3 cells may be because of the differences in IGF-1R
levels that are responsive to 13-(S)-HODE concentration.
Similarly, we have previously found that 15-LO-1 enzyme
is present in high levels in the epithelium of prostate
adenocarcinoma compared to normal surrounding tissues.
The level of 15-LO-1 expression is strongly correlated with
the degree of malignancy, as assessed by Gleason grades
[6]. In order to study if the IGF-1R levels also correlated with
the degree of malignancy, we immunohistochemically ana-
lyzed (n = 26) 10 (benign prostatic hyperplasia or BPH) and
16 adenocarcinoma tissues (Gleason grade = 8–10) of
human prostate from different patients for IGF-1R localiza-
tion. Therefore, we did not compare IGF-1R localization
between simple prostatectomy–derived BPH tissues and
the high-grade tumor specimens in the same patients.
Nevertheless, 15-LO-1 expression is low in BPH and normal
tissues, and high in the high-grade tumors of Gleason
grades 8 to 10 [6].
Figure 1. (A). 13-(S)-HODE rescues inhibition of 15-LO-1 enzyme caused by
1 M PD146176. PC-3 cells were grown in (1) medium alone ( ); (2) medium
+ 10 M 13-(S)-HODE ( ); (3) medium + inhibitor ( ); and (4) medium +
inhibitor + 10 M 13-(S)-HODE (n), for 72 hours (after every 12 hours,
replaced appropriately by fresh media). Cell death is assessed by Trypan
blue exclusion assay, versus survival, by MTT assay. The data shown are
mean ± SE of six determinations. *P < .05, **P < .01, ***P < .02. (B). Effect of
growth factors on PC-3 cell proliferation. PC-3 cells were treated with growth
factors in growth medium. Medium  FBS (A) ( ); A + FGF (5 ng/ml) (n); A
+ PDGF (10 ng/ml) ( ); A + IGF-1 (10 ng/ml) ( ). Proliferation was
assessed by MTT assay. The data shown are mean ± SE of six
determinations. *P < .01.
.
.
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Therefore, this study may have limitations, and there
may be differences in the immunophenotypic (histologic)
alterations in IGF-1R levels in benign and tumor tissues from
different patients versus data compared in the same
patients. The prostate tumor tissues we analyzed display
a higher expression of IGF-1R in cancerous foci (highly
proliferating cells) compared to BPH tissues (representatives
shown in Figure 2, Panel 1A; some foci negative for IGF-1R
versus Panel 1B), further quantitatively assessed by image
cytometry analyses (Table 1). The most striking differences
in the IGF-1R localizations were observed in BPH prostate
compared to cancer tissues. There is uniform immunostain-
ing in the stratified luminal epithelium in the benign gland in
Figure 2, Panel 1A versus an extensive immunostaining in
the infiltrative tumor as shown in Figure 2, Panel 1B. The
IGF-1R is predominantly localized in the glandular epithelium
of benign tissues, whereas in adenocarcinomas, it is mainly
localized and upregulated in highly proliferating epithelial
cells (Table 1), and this is proportional to 15-LO-1 expression
we have previously observed [6,17]. These results demon-
strate that although specific binding sites for IGF-1 are
present, both in the benign as well as adenocarcinoma
prostatic tissues, higher IGF-1R levels are associated with
high-grade prostate tumor epithelial cells.
15-LO-1 Expression Caused Concomitant Increase in
IGF-1R Levels as Well as IGF-1R Activation
We further measured differences in IGF-1R levels by
immunohistochemistry (DAB staining brown) in tumors
from an experiment with nude mice injected with individual
PC-3 cells (same PC-3 cells as previously described) [17].
We found the levels of IGF-1R in the primary tumors to be:
PC3-15LOS > PC3 = PC3-Zeo > PC3-15LOAS (represen-
tatives shown in Figure 2, Panel 2). These observations
further supported the possible relationship between IGF-1R
and 15-LO-1, and their roles in PC-3 cell growth. Based on
these results, we studied whether 15-LO-1 overexpression
caused an increase in the number of available receptors for
ligand (i.e., IGF-1) binding or not. We examined the IGF-1R
levels by [125I]IGF-1 ligand binding assay, in the presence or
absence of cold IGF-1 (5–100 nM). Our results (n = 4), as
shown in Figure 3A, suggest that PC3-15LOS (15-LO-1–
overexpressing) cells have greater than two-fold to three-fold
number (P < .05 vs PC3-Zeo) of IGF-1 binding sites (25 ± 4
fmol/105 cells) versus those in both PC3-Zeo (7 ± 3 fmol/105
cells) and parental PC-3 (8 ± 2 fmol/105 cells), respectively.
However, although not significantly, the binding sites in PC3-
15LOAS cells (6 ± 3 fmol/105 cells) were reduced (Figure 3A).
This experiment suggests that 15-LO-1 overexpression
caused an upregulation of IGF-1R.
One of the primary steps in signaling pathway(s) is the
phosphorylation status of receptor(s) required for activation
of its receptor complex. To evaluate whether 15-LO-1 over-
expression is also causal to IGF-1R activation (phosphory-
lation status), we first immunoprecipitated IGF-1R from the
total proteins extracted from PC-3 cells (n = 4) using IGF-1P,
and then performed Western blot analyses using IGF-1P
antibody for measuring the IGF-1R levels. Similarly, we also
determined the phosphorylation status, using a phosphotyro-
sine antibody (Figure 3B). As assessed by densitometry
scanning, the IGF-1R receptor levels were three-fold higher
in PC3-15LOS (15-LO-1–overexpressing) cells versus the
PC3-15LOAS, PC-3 parental or PC3-Zeo (control) cells
(Figure 3B1). Also the IGF-1R receptors from PC3-15LOS
(15-LO-1–overexpressing) cells were phosphorylated four-
fold compared to the PC3-Zeo or PC-3 cells (Figure 3B2).
Thus, 15-LO-1 overexpression in PC-3 (PC3-15LOS) cells
increases IGF-1R expression and therefore phosphorylation.
15-LO-1 Expression Caused an Increase in IGF-1R
Promoter Activation
To elucidate the mechanism for the increased IGF-1R
expression, we measured IGF-1R promoter activation in
PC-3, PC3-Zeo, PC315LOS, and PC3-15LOAS cells using
a luciferase assay (Figure 3C ). PC3-15LOS (15-LO-1–over-
expressing) cells displayed four-fold higher levels of IGF-1R
promoter activation (n = 6, P < .01 vs the PC3-Zeo), whereas
PC315LOAS (in which 15-LO-1 is blocked) displayed de-
creased IGF-1R promoter activation (Figure 3C ).
In order to further test whether the observed IGF-1R
promoter activation is 13-(S)-HODE–specific, the PC3-Zeo
cells were similarly transfected as described above. Twenty-
four hours after IGF-1R reporter vector transfection, the
PC3-Zeo cells were individually treated with increasing
concentrations (10, 34, 67, and 135 mM) of 13-(S)-HODE
and allowed to grow over a 36-hour time period. Lucifer-
ase activity assays were performed as described above.
We observed a concentration-dependent increase in lucif-
erase activity from 10 to 34 mM 13-(S)-HODE–treated
cells versus untreated control (Figure 3D). These results
further supported our observation as depicted in Figure 3,
A–C, respectively.
However, although the reporter activity increased three-
fold from 10 to 34 mM, and was then slightly higher in 135 mM
compared to 10 mM 13-(S)-HODE–treated PC3-Zeo cells,
the reporter activity significantly decreased from 34 to 135 mM
(Figure 3D; P < .02) respectively. No obvious cell death or
apoptosis was observed in any of these cells (data not
shown). These data suggest that 15-LO-1 expression and,
consequently, 13-(S)-HODE can affect IGF-1R transcription.
At lower physiological levels (up to 34 mM), 13-(S)-HODE
increases transcription of IGF-1R, whereas at high nonphy-
siological levels (greater than 34 mM), 13-(S)-HODE causes
downregulation of IGF-1R. Therefore, it is intriguing to spec-
ulate that there could be a central role for 13-(S)-HODE–
dependent regulation of IGF-1R, and therefore a fundamental
role of 15-LO-1 in prostate cell proliferation.
Blocking 15-LO-1–mediated IGF-1R Levels Inhibited the
Proliferation of PC-3 Cells
From the results of our experiments, it was imperative
to determine whether targeting IGF-1R can potentially
block PC-3 cell proliferation. In order to address this, we
used a recombinant adenovirus, AdTrackCMV-DNIGF-1R-
GFP, which contains a dominant-negative a chain of the
IGF-1 receptor to block IGF-1R expression in PC-3 cells.
15-Lipoxygenase-1 Upregulates Insulin-like Growth Factor-1 Receptor Kelavkar and Cohen 45
Neoplasia . Vol. 6, No. 1, 2004
Vector alone (pAdTrackCMV-GFP) is used as the control.
Fortunately, the high degree of homology of IGF-1R in
humans and rats [26] allows a dominant-negative IGF-1R
from rats to be used in studies of human cells [27,28].
IGF-1 at 10 ng/ml was the mitogenic stimulant. Serum-
starved PCa cell lines (i.e., parental PC-3, PC3-Zeo,
PC315LOS, and PC3-15LOAS cells) were treated in vitro
(n = 6), in the presence of IGF-1 and appropriately with
Table 1. Histologic Analyses of IGF-1R Immunostaining in Human Prostate Tissues and Tumors from Nude Mice.
Human prostate tissues Tumors from Nude mice
Normal
(BPH)
(n = 10)
Prostate tumors
[Gleason 8–10]
(n = 16)
PC3-parental
(n = 4)
PC3-Zeo
(n = 4)
PC3-15LOS
(n = 8)
PC3-15LOS
(n = 8)
++
(predominantly
glandular epithelium)
++++
(focal expression
in highly proliferating
epithelium)
++ ++ ++++ +
The results were analyzed by image cytometry and semiquantitatively measured as 0 to 4+: 0—no staining; 1+—weak intensity staining; 2+—moderate intensity
staining in less than one-half of the cells, but less than strong uniform staining; 3+— intense staining in all cells, but less than strong/robust uniform staining; 4+—
strong/robust uniform staining in all tissue/cells.
Figure 2. Representative immunohistochemistry of human prostate tissues with IGF-1 receptor antibody. Panel 1: Immunostaining (brown, shown by arrows) of (A)
normal and (B) adenocarcinoma tissues of human prostate (n = 26); 10 normal and 16 adenocarcinoma tissues of Gleason grade = 8 to 10, with polyclonal antibody for
IGF-1R (original magnification, 200). The values are reported as assessed by image cytometric quantitation (Table 1). Panel 2: IGF-IR Immunohistochemistry ot
tumors in nude mice. Immunostaining (brown, indicated by arrows) of tumors, from nude mice caused by PC3-15LOS, PC3-15LOAS, PC-3 parental and mock-
transfected PC3-Zeo, with IGF-1R polyclonal antibody (original magnification,200). The values are reported as assessed by image cytometric quantitation (Table 1).
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AdTrackCMV-DNIGF-1R-GFP and pAdTrackCMV-GFP
adenoviruses, each at a concentration of 1.16  1011 pfu,
respectively.
The objective was also to determine whether inhibition of
IGF-1R blocked growth of PC-3 cells even though 15-LO-1
is active. After treatment of PC-3 cells with AdTrackCMV-
DNIGF-1R-GFP (expressing the dominant-negative
IGF-1R), there was significant growth inhibition of PC3-
15LOAS cells (P < .0001 vs PC3-15LOS cells similarly
treated) compared to cells similarly treated with the empty
adenoviral vector, pAdTrackCMV-GFP, as control. Thus,
inhibition of growth was more pronounced in PC-3 cells
expressing inactive 15-LO-1 (PC3-15LOAS), PC-3 parental,
and PC3-Zeo cells compared to the PC-3 cells overexpress-
ing 15-LO-1 (PC3-15LOS) (Figure 4). Overall, these results
supported our hypothesis and suggest that the efficacy of
growth inhibition by IGF-1R blockade was dependent on
15-LO-1 levels.
Blocking 15-LO-1–dependent IGF-1R Levels Inhibited the
IGF-1/MAP Kinase Signaling and Proliferation of PC-3 Cells
Furthermore, 15-LO-1–dependent IGF-1R activation
could lead to stimulation of the downstream signaling path-
way(s). In order to study this, we compared the activation
levels of mitogen-activated protein kinase (MAPK or Erk1/2)
and Akt enzymes in PC3-Zeo cells (control) with those in
15-LO-1–overexpressing PC3-15LOS cells (Figure 5). We
used the same adenovirus strategy in order to block IGF-1R.
Specifically, serum-starved PCa cell lines (i.e., PC3-Zeo
and PC3-15LOS) were individually grown with or without
Figure 3. (A) IGF-1R expression levels in PC-3 cells. Radiolabeled IGF-1 binding to PC-3 cells was performed. Cells (100,000 cells/ml) were incubated for 30
minutes at 37 8C with [125I]IGF-1, in the presence or absence of different concentrations (5–100 nM) of cold IGF-1. After incubation, the cells were washed with ice-
cold Hepes buffer, lysed in 0.1 M NaOH, and counted by c-counter. Data are analyzed by ligand program. Results shown are the mean ± SE of four separate
experiments. *P < .01. (B) Western blot analyses of immunoprecipitated IGF-1R from PC-3 cells. Equal protein (1 mg, total protein) from each PC-3 cell line was
immunoprecipitated by an antibody specific for IGF-1P (N-20), resolved on 10% SDS-PAGE, and immunoblotted by the N-20 antibody (shown in B1), and the same
blot by anti –phosphotyrosine antibody PY-7E1 for tyrosine-phosphorylated proteins, respectively (shown in B2). Ponceau S staining of the blots was conducted to
ensure equivalent loading. Protein levels and phosphorylation were measured by densitometry. The data shown are representative of three independent
experiments. The values ± standard deviation are reported in the brackets below the gels. (C) 15-LO-1–dependent activation of the IGF-1R promoter. The
indicated cells were transiently transfected with a plasmid containing the luciferase gene driven by base pairs 2350 to +640 of the rat IGF-1R promoter region,
along with a Renilla expression vector as a control for transfection efficiency. The luciferase activity, as a measure of IGF-1R activation, was normalized to Renilla
in each case. Results shown comparing the IGF-1R promoter activity in parental PC-3, PC3-Zeo, PC3-15LOS, and PC3-15LOAS cells are the mean ± SE of six
separate experiments. *P < .01. (D) 13-(S)-HODE–dependent activation of the IGF-1R promoter. The PC3-Zeo cells were transiently transfected with rat IGF-1R
promoter – reporter plasmid as described for (C), and after 24 hours posttransfection, they were individually treated (exogenously added) with increasing
concentrations (10, 34, 67, and 135 M) of 13-(S)-HODE respectively, and allowed to grow further until 36 hours. The luciferase activity, as a measure of IGF-1R
activation, was normalized to Renilla in each case. Results shown comparing the IGF-1R promoter activity in parental PC-3, PC3-Zeo, PC3-15LOS, and PC3-
15LOAS cells are the mean ± SE of six separate experiments. ***P < .02.
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10 ng/ml IGF-1, in the presence and absence of Ad-
TrackCMV-DNIGF-1R-GFP and pAdTrackCMV-GFP (con-
trol) adenoviruses, and assayed for their ability to proliferate,
as depicted in Figure 5. Total Erk1/2 (MAP kinase) and Akt
protein levels as well as their corresponding activation
(phosphorylation) status using phospho-Erk and phospho-
Akt were determined in these cells by immunoblotting and
quantitated by densitometry scanning.
Our results demonstrate that IGF stimulation and subse-
quent treatment with the adenovirus, pAdTrackCMV-GFP,
as control dramatically increased (8- to 10-fold) Erk1/2
activation (Figure 5, lane 5 ) in PC3-15LOS (15-LO-1–over-
expressing) cells versus PC3-Zeo cells (Figure 5, lane 1),
whereas no difference was seen in Akt activation. Further-
more, the activation of Erk1/2 by IGF-1 is partially blocked by
AdTrackCMV-DNIGF-1R-GFP, whereas an increase in Akt
activation is detected in both the cell lines (Figure 5, lane 3
compared to lane 7 ). In both the unstimulated PC-3 cells (but
treated with adenovirus pAdTrackCMV-GFP as control),
activated Erk1/2 and Akt at low levels were detected,
but only Erk1/2 were higher in PC3-15LOS compared to
PC3-Zeo cells (Figure 5, lane 2 compared to lane 6).
However, in a similar comparison of unstimulated PC-3
cells in which IGF-1R is blocked by AdTrackCMV-DNIGF-
1R-GFP, the activation of endogenous Erk1/2 is not
completely blocked, but interestingly, an increase in Akt
activation is detected in both cell lines (Figure 5, lane 4
compared to lane 8). These results suggest that blocking
of 15-LO-1–induced increase in IGF-1R expression leads
to inhibition of MAP kinase activation in the presence of
IGF-1. Thus, these results support our hypothesis that
IGF-1R levels and the downstream signaling pathway(s)
are affected by 15-LO-1 expression status, and by block-
ing IGF-1R or possibly inhibiting 15-LO-1 activity, we can
alter the proliferation status of PCa cells.
Discussion
The 15-LO-1 metabolic product of LA, 13-(S)-HODE, has
been shown to participate in signaling processes [8–24]; a
direct role of this lipid metabolite in prostate cellular prolif-
eration is unknown. De Vries and van Noorden [33]
reported that long-chain PUFAs of the n3 family [e.g.,
eicosapentaenoic acids (C20:5n3) and docosahexaenoic
acids (C22:5n3)] inhibit prostate tumor growth whereas
Figure 5. 15-LO-1 overexpression modulates IGF-1R levels that cause an increase in MAP kinase activation. Western blot analysis of protein (25 g/well) from
PC3-Zeo (mock-transfected) compared to PC3-15LOS cell line, treated with (+) and without () IGF-1 (10 ng/ml) in the presence of adenovirus vector alone
(pAdTrackCMV-GFP) and the IGF-1R blocking adenovirus (AdTrackCMV-DNIGF-1R-GFP) (1.16  1011 pfu) by (A) an antibody specific for phospho-Akt (Ser 473)
and for Erk-1/2 (i.e., phospho-p44/42 MAP kinase) (Thr 202/Tyr 204) and (B) an antibody for total Akt and Erk-1/2. Ponceau S staining of the blots was conducted
to ensure equivalent protein loading. The data shown are representative of three independent experiments.
Figure 4. Effect of IGF-1R blocking on growth of PC-3 cells. PC-3 cells were
grown for 48 hours in 1 ml of medium + FBS, washed, and then grown further
in serum-starved medium + IGF-1 (10 ng/ml) and treated with adenoviral
vectors pAdTrackCMV-GFP (control) and AdTrackCMV-DNIGF-1R-GFP
(both at a concentration of 1.16  1011 pfu), and grown further for 48 hours
in medium (FBS). Percentage increase in growth (treated with pAd-
TrackCMV-GFP alone) = (OD after 96 hours  OD after 48 hours) / OD
after 48 hours. Percentage decrease in growth (treated with AdTrackCMV-
DNIGF-1R-GFP) = (OD after 96 hours  OD after 48 hours) / OD after 48
hours. The data shown are mean ± SE of six independent determinations of
MTT assays. *P < .0001.
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metastasis is promoted by long-chain n6 PUFAs [e.g., LA
(C18:2n6)]. Others have reported that LA supports the
growth of both the androgen-unresponsive PC-3 and the
androgen-responsive DU145 human PCa cell lines in vitro
and in athymic mice [31–34].
Results presented in this study demonstrate for the first
time that 13-(S)-HODE can cause an increase in the
expression of IGF-1R in prostate carcinoma cells. This, in
turn, can trigger prostate cell proliferation and/or migration.
This could explain why PCa cells express IGF-1R and often
metastasize to bone stroma, an environment rich in IGFs.
In short, 15-LO-1 overexpression can augment IGF-1 to
exert a paracrine action in PCa cell proliferation and
migration, and may have a profound impact in prostate
carcinogenesis. In the prostate, as is the case with other
glandular and nonglandular tissues, epithelial –stromal
interactions are an essential feature of normal morphogen-
esis and cytodifferentiation [35,36]. Furthermore, there is
growing evidence that stromal factors contribute to the
evolution of PCa [37]. Although 15-LO-1 preferentially
was able to rescue the PC-3 cells’ growth inhibition caused
by the 15-LO-1 enzyme inhibitor, PD146176, added in vitro,
it can be inferred that 13-(S)-HODE can also act as a
survival factor for PC-3 cells, possibly via modifying the
levels of the anti–apoptotic gene, BCL2 [23]. Although it is
unknown whether 13-(S)-HODE is also present in all stro-
mal cells or not, Rao et al. [38] have reported that LA and
its product, HODE, in smooth muscle cells induced DNA
synthesis and c-fos, c-jun, and c-myc mRNA expression,
and caused MAPK activation, leading to proliferation. Re-
gardless, it is intriguing to speculate that 13-(S)-HODE
secreted by proliferating prostate epithelial cells could also
interact with stromal cells and play an important role in the
evolution of PCa progression.
Furthermore, when PC-3 cells were exposed to growth
factors in serum-free medium, namely PDGF, IGF-1, and
bFGF, PC3-15LOS (15-LO-1 – overexpressing) cells
exhibited a two-fold to three-fold greater response to IGF-1
in 72 hours (Figure 1B). These results suggested that the
proliferation in 15-LO-1–overexpressing cells is possibly
modulated by IGF-1 through IGF-1R. There is also substan-
tial evidence that IGF-1R signaling is involved in antiapo-
ptosis [39–41]. Previously published reports [42,43] indicate
that cells lacking IGF-1R fail to grow in serum-free medium
supplemented with growth factors (i.e., PDGF, TGF, EGF,
insulin, IGF-1, or bFGF, separately or in a combination).
Baserga et al. [42] reported that IGF-1R is required for
optimal growth throughout the phases of cell cycle, and that
the expression of IGF-1 and IGF-1R is regulated by tumor-
suppressor genes WT1 and RB [42] and wild-type p53 [43].
These findings suggest that activation of the IGF-1R is
an absolute requirement for growth factors to exert their
mitogenic effects.
Immunohistochemical analyses of human benign and
adenocarcinoma prostate tissues (Figure 2, Panel 1) and
tumors derived from nude mice subcutaneously injected with
PC-3 cells (Figure 2, Panel 2) suggest that: 1) IGF-1R
expression in tumors correlated with 15-LO-1 levels; and 2)
although IGF-1R is present in benign and adenocarcinoma
prostatic tissues, in high-grade tumor cells, their epithelial
localization seems to be specifically modified (i.e., from
glandular epithelium in benign versus highly proliferating
epithelial cells in adenocarcinoma) [44,45]. The growth hor-
mone (GH)/IGF-1 axis has a clearly established role in
somatic growth regulation, and there is evidence suggesting
that it can play a role in neoplastic tissue growth [46].
Epidemiologic studies suggest an association between in-
creased serum levels of IGF-1 and an increased risk of PCa
[47,48].
Ligand binding (Figure 4), Western blot analysis
(Figure 3B), and IGF-1R promoter activation assays
(Figure 3C) in PC-3 cells demonstrated the levels of IGF-1R
and their corresponding activation (phosphorylation) status
as: PC315LOS > PC-3 = PC3-Zeo > PC3-15LOAS. Impor-
tantly, PC3-15LOS displayed greater than two-fold number
of receptors that were four-fold activated. Further study to
determine the specificity of 13-(S)-HODE for IGF-1R upregu-
lation revealed a concentration-dependent increase in the
reporter activity by 10 and 34 mM 13-(S)-HODE, respectively
(Figure 3D). However, gradual but significant reduction of
reporter activity is noted with exogenously added 13-
(S)-HODE at 67 and 135 mM concentration, suggesting that
a 34-mM concentration was optimum to support cellular
proliferation and higher concentrations in this property. Even
though we did not observe cell death or apoptosis in these
cells after 12 hours of exposure to higher concentrations of
13-(S)-HODE, we suspect that the cells may have undergone
growth arrest and therefore reflect decreased reporter activ-
ity. Although it remains to be seen how much endogenous
13-(S)-HODE concentration is actually produced by cultured
PC-3 cells in vitro or in PCa tissues (in vivo) to impart a
biologic effect, these results support our hypothesis and
further demonstrate a direct correlation between 15-LO-1
expression and IGF-1R levels in PCa cells. Human PCa cell
lines, PC-3, and DU-145 express IGF-1 receptors [49] and
are inhibited by an IGF-1 receptor–specific monoclonal anti-
body [50]. Similarly, IGFs are paracrine growth stimulators in
both the normal and the hyperplastic PCa cells [51,52].
Recently, a more direct study of transgenic mice expressing
human IGF-1 in basal epithelial cells of prostate led to
activation of IGF-1R and spontaneous tumorigenesis in pros-
tate epithelium [53,54]. This phenomenon may be dependent
on the PI3 kinase and/or MAP/Erk kinase pathway [55–58].
It is conceivable that there could be a central role for
13-(S)-HODE–dependent regulation of IGF-1R levels and,
consequently, its role in the transformation of normal
prostate epithelial cells to a dysregulated, mitogenic, pro-
liferative state. When the IGF-1R is blocked, there is
inhibition in growth of all PC-3 cells, except that the over-
expressing 15-LO-1 (PC3-15LOS) requires a higher con-
centration of blockade for complete growth/proliferation
inhibition. Thus, there is a positive association between
13-(S)-HODE–dependent activation of the IGF-1R path-
way and growth. This phenomenon may occur by: 1) acti-
vating the 13-(S)-HODE–dependent downstream signaling
pathway; and/or 2) preventing apoptosis.
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Recently, Hsi et al. compared the effects of 13-(S)-
HODE, a 15-LO-1/LA metabolite, to the effects of 15-(S)-
HETE, a 15-LO-2/arachidonic acid metabolite, on MAP
kinase signaling and PPARg levels in our PCa cell line
PC-3, and showed that 13-(S)-HODE upregulated whereas
15-(S)-HETE downregulated MAP kinase [24]. Thus,
depending on the available substrate (i.e., LA versus arach-
idonic acid), the 15-LO metabolites have opposing effects
on the regulation of the MAP kinase signaling pathway that
affects PPARg, which is the downstream target of MAP
kinase pathway.
Comparing PC3-15LOS cells versus PC3-Zeo, the ro-
bust stimulation of Erk1/2/MAPK by IGF-1 and subsequent
reduction in MAP kinase activation by IGF-1R blockade
suggest a 15-LO-1–dependent IGF-1R activation (Figure 4).
However, it seems evident that Erk1/2 activation was not
solely dependent on IGF-1 or IGF-1R activation, but also by
15-LO-1–dependent mechanism(s) (Figure 5). These
observations suggest that the basal Erk1/2 activation is
15-LO-1–dependent and can also occur through a mech-
anism(s) or pathway(s) independent of IGF-1R. What is
also interesting is that increased activation levels of the
‘‘survival kinase’’ Akt by IGF-1 (from the basally activated
levels; i.e., without IGF-1) are observed in both PC3-Zeo
and PC3-15LOS cells, suggesting that Akt activation does
not seem to be solely dependent on 15-LO-1 expression,
but is IGF-1–dependent.
It is unclear and remains to be demonstrated as to how
and why IGF-1R blockade alone, as well as the IGF-1R
blockade in concert with IGF-1, activate the survival protein,
Akt. Consequently, it also remains to be seen whether the
MAPK/Akt and IGF-1 interactions are governed by an as yet
unidentified 13-(S)-HODE receptor, or whether it is a conse-
quence of 13-(S)-HODE binding directly to the IGF-1R in the
membranes. Although one or both possibilities could exist, it
is conceivable that 13-(S)-HODE could interact with cis- or
trans-acting elements that regulate IGF-1R expression be-
cause we observed that 13-(S)-HODE caused an increase in
IGF-1R promoter–reporter activity (Figure 3D). Interestingly,
a recent study by Kiely et al. [59] has shown that the receptor
for activated C kinases (RACK1) is an IGF-1R–interacting
protein that can modulate receptor signaling and that RACK1
has a role in regulating Akt activation and cell survival.
RACK1 interacts with the IGF-1R to negatively regulate
activation of the PI3-K pathway but has a positive effect on
activation of theMAP kinase and JNK pathways. It is possible
that RACK1 and its associated proteins may interact with
13-(S)-HODE to regulate MAPK signaling through IGF-1R.
Overall, these experiments confirm that increased levels
and therefore phosphorylation of IGF-1R by 13-(S)-HODE
transmitted signals downstream through the MAP kinase
signaling pathway. Thus, our present study suggests that
the ability of the transforming agent, IGF-1, to exert growth-
promoting/proliferative effects in PCa cells is exacerbated by
the 15-LO-1 metabolic product, 13-(S)-HODE. The proposed
model for interaction of 13-(S)-HODE with the IGF-1R and
the signaling pathway is summarized in Figure 6. Further
experiments are required to study the downstream signaling
pathway(s) and the proliferation status mediated through
15-LO-1 metabolites and IGF-1R in PCa cells. Ultimately, a
drug/blocker targeted to directly inhibit 15-LO-1 activity may
have therapeutic benefit against PCa, which becomes large-
ly refractory to conventional chemotherapeutic strategies.
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